Additionally, Phase 1b TROPION-Lung04 results, presented earlier on May 31, showed that DATROWAY combined with AstraZeneca’s rilvegostomig achieved a 57.5% ORR and 95% disease control rate in 40 ...

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it failed to prolong the lives of patients in a late-stage study, the ...

Merck and Daiichi Sankyo, which were seeking approval of patritumab deruxtecan for adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer previously treated with two or ...

Daiichi Sankyo Co. Ltd. and Merck & Co. Inc. have voluntarily pulled the BLA for accelerated approval tied to their HER3-directed antibody-drug conjugate (ADC) in treating EGFR-mutated ...

Daiichi Sankyo will hold a virtual conference call for investors on Monday, June 2, 2025 from 6:00 to 7:15 pm CDT / Tuesday, June 3, 2025 from 8:00 to 9:15 am JST.

Daiichi Sankyo is a commercial-stage biopharmaceutical company that is in strong financial health. As of fiscal 2024, it had a debt/EBITDA ratio of 0.3 times and over JPY 700 billion in cash and ...

Enhertu is currently approved as a second-line treatment for HER2-positive metastatic breast cancer. The new results for the AstraZeneca and Daiichi Sankyo drug in the first-line setting are ...

Daiichi Sankyo’s oncology goals He added that the drugmaker has “big aspirations” in the cancer treatment space, including a goal to become a top 10 oncology company worldwide within the next five ...

Daiichi Sankyo has a 12 month low of $20.92 and a 12 month high of $42.48. The company has a current ratio of 2.77, a quick ratio of 2.11 and a debt-to-equity ratio of 0.06.

Daiichi Sankyo Company, Limited leads in ADC tech with Enhertu, strong partnerships, revenue growth, and global market leadership. Click to know more on why DSNKY is a Buy.

WASHINGTON (7News) — Daiichi Sankyo Inc., an innovative pharmaceutical company's deep ties to the Cherry Blossoms in Washington, DC dates back more than a century to the company's first ...

Daiichi Sankyo, AstraZeneca’s Enhertu approved in European Union TipRanks Apr. 4, 2025, 04:00 AM ...